| 1. | | No longer recruiting | "Clinical Trials to Enhance Elders' Oral Health" ("TEETH")
Conditions: Tooth Loss; Periodontal Disease; Tooth decay |
| 2. | | Completed | A "Pre-Enrollment" Protocol for HIV-Infected Adolescents
Condition: HIV Infections |
| 3. | | Recruiting | The "Reach For Health" Program: Delaying Sexual Activity in Children
Conditions: Sex Behavior; Child Behavior |
| 4. | | Recruiting | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk
Condition: Prostate Cancer |
| 5. | | No longer recruiting | (1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients who Receive Neurotoxic Therapy
Conditions: Cancer; Central Nervous System Disease; Nervous System Disease; Peripheral Nervous System Disease; Progressive Multifocal Leukoencephalopathy |
| 6. | | Completed | (PET) Imaging in the Management of Patients with Solitary Pulmonary Nodules
Condition: Benign and malignant solitary pulmonary nodules |
| 7. | | Completed | (Ro 24-2027) A Randomized, Double-Blind, Comparative Study of Dideoxycytidine (ddC) versus Zidovudine (AZT) in Patients With AIDS or Advanced ARC
Condition: HIV Infections |
| 8. | | Completed | 1-Octanol to Treat Essential Tremor
Condition: Essential Tremor |
| 9. | | Completed | 1-Octanol to Treat Essential Tremor
Condition: Essential Tremor |
| 10. | | No longer recruiting | A 1-Year Study of an Investigational Drug in Obese Patients
Condition: Obesity |
| 11. | | Suspended | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma |
| 12. | | No longer recruiting | 10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer; Quality of Life |
| 13. | | Completed | 10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 14. | | No longer recruiting | 12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
Condition: Hepatitis C |
| 15. | | Completed | 12 week,comparing safety of HMR1964 & insulin aspart used in continuous subcutaneous infusion in type 1 diabetes.
Condition: Diabetes, type I |
| 16. | | Recruiting | 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm |
| 17. | | No longer recruiting | A 12-week, multicenter, safety and dose-ranging study of 3 oral doses of TCH346 in patients with Amyotrophic Lateral Sclerosis
Condition: Amyotrophic Lateral Sclerosis |
| 18. | | Recruiting | 131MIBG to Treat Malignant Pheochromocytoma
Condition: Pheochromocytoma |
| 19. | | Recruiting | A 14-day study of Racivir when used in combination in HIV-Infected Males
Condition: HIV Infections |
| 20. | | Recruiting | 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer |
| 21. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer |
| 22. | | Recruiting | 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma |
| 23. | | Recruiting | 17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma |
| 24. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Condition: unspecified adult solid tumor, protocol specific |
| 25. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer |
| 26. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma |
| 27. | | Not yet recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer |
| 28. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ... |
| 29. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma
Conditions: stage III melanoma; Stage IV Melanoma; Recurrent Melanoma |
| 30. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome |
| 31. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma |
| 32. | | Recruiting | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ... |
| 33. | | Recruiting | 17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer |
| 34. | | Recruiting | 2 doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting
Condition: Postoperative Nausea and Vomiting |
| 35. | | Recruiting | 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting
Condition: Postoperative Nausea and Vomiting |
| 36. | | No longer recruiting | 2-Methoxyestradiol (2-ME2) to Treat Solid Tumor Cancers
Conditions: Pathologic Angiogenesis; Neoplasm |
| 37. | | Recruiting | 2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific |
| 38. | | No longer recruiting | A 2-Year Study of an Investigational Drug in Obese Patients
Condition: Obesity |
| 39. | | Recruiting | A 20-week study of a new treatment for men with Benign Prostatic Hyperplasia (BPH).
Condition: Prostatic Hyperplasia |
| 40. | | Recruiting | A 24 Week Study of Daily Oral Investigational Drug vs Placebo in Patients with Asthma
Condition: Asthma |
| 41. | | Completed | A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients with AIDS
Conditions: Cryptosporidiosis; HIV Infections |
| 42. | | No longer recruiting | 3 Different Dose Levels of CCI-779 in Subjects with Active Rheumatoid Arthritis on Concomitant Methotrexate Therapy
Condition: Rheumatoid Arthritis |
| 43. | | Recruiting | 3 Fixed Dosages of Extended Release OROS Paliperidone and Olanzapine in the Treatment of Subjects with Schizophrenia
Condition: Schizophrenia |
| 44. | | No longer recruiting | 3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 45. | | Not yet recruiting | 3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer |
| 46. | | No longer recruiting | 3-AP and Cytarabine in Treating Patients With Hematologic Cancer
Conditions: acute leukemia; atypical chronic myeloid leukemia; chronic leukemia; myelodysplastic and myeloproliferative disease |
| 47. | | Recruiting | 3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Condition: unspecified adult solid tumor, protocol specific |
| 48. | | Recruiting | 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer |
| 49. | | Recruiting | 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
Condition: Non-small cell lung cancer |
| 50. | | Recruiting | 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer |
